Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer

The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Bevacizumab 7.5 and TAC; Drug: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC); Drug: Bevacizumab 15 and TAC; Drug: Placebo 15 and TAC

Detailed Description

The study combines bevacizumab with a very efficacious combination chemotherapy regimen for the treatment of stage II or stage III primary breast cancer. Safety of the TAC-bevacizumab combination will be evaluated. In addition, the study design incorporates an initial cycle of bevacizumab or placebo alone. Assessing the isolated effects of bevacizumab in a setting where pre- and post-treatment tissue specimens can be obtained will provide essential information about the mechanisms by which VEGF inhibition affects tumor growth, and represents an ideal opportunity to evaluate the molecular effects of bevacizumab on breast tumor tissue.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Cross Cancer Institute
  • Quebec
    • Montreal, Quebec, Canada, H2W 1S6
      • McGill University
• Ireland
  • Dublin, Ireland, 4
    • St. Vincent's University Hospital
  • Dublin, Ireland, 8
    • St. James's Hospital
• United States
  • California
    • Los Angeles, California, United States, 90095
      • UCLA Medical Center
    • Pomona, California, United States, 91767
      • Wilshire Oncology Medical Group, Inc.
  • Florida
    • Orlando, Florida, United States, 32804
      • Cancer Institute of Florida, P.A.
  • Georgia
    • Marietta, Georgia, United States, 30060
      • Northwest Georgia Oncology Centers, P.C.
  • Texas
    • San Antonio, Texas, United States, 78207
      • South Texas Oncology and Hematology, P.A.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Histologically or cytologically proven adenocarcinoma of the breast
• Stage II (T > 3 cm) or Stage III disease (except inflammatory breast cancer), according to the AJCC Staging Manual, 6th Edition, 2002
• HER2-negative disease (as defined by fluorescence in situ hybridization [FISH])
• ECOG performance status 0-1
• No prior chemotherapy, radiotherapy, or endocrine therapy for invasive or noninvasive breast cancer
• Normal cardiac function (ejection fraction > lower limit of normal) as determined by MUGA or echocardiogram
• Adequate organ function

Exclusion Criteria:

• Prior chemotherapy or radiotherapy for Stage II or Stage III breast cancer
• Inflammatory Breast Cancer, clinically defined as the presence of erythema or induration involving one-third or more of the breast
• Prior treatment with an anti-angiogenic agent
• Prior ipsilateral radiation therapy for invasive or non-invasive breast cancer
• Bilateral invasive breast cancer
• Concurrent therapy with any other non-protocol anti-cancer therapy
• Current therapy with hormone replacement therapy, or any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (agents must be stopped prior to randomization)
• Presence of neuropathy > grade 2 (NCI-CTC version 3.0) at baseline
• Presence of any non-healing wound, bone fracture, or ulcer, or the presence of clinically significant (> grade 2) peripheral vascular disease
• History of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix
• Clinically significant cardiovascular disease (e.g., hypertension [BP > 150/100], myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
• Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning therapy
• Active, uncontrolled infection requiring parenteral antimicrobials
• The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
• Pregnancy or lactation
• A history of a severe hypersensitivity reaction to bevacizumab, or docetaxel or other drugs formulated with polysorbate 80
• Evidence of bleeding diathesis or coagulopathy
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to beginning therapy
• Urine protein:creatinine ratio of > 1.0 at screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Bevacizumab 7.5 and TAC; one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.	Drug: Bevacizumab 7.5 and TAC; Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
Placebo Comparator: Placebo 7.5 and TAC; Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.	Drug: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC); placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
Experimental: Bevacizumab 15 and TAC; one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.	Drug: Bevacizumab 15 and TAC; one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
Placebo Comparator: Placebo 15 and TAC; Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.	Drug: Placebo 15 and TAC; one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
•To evaluate the safety and toxicity of the TAC regimen with the addition of bevacizumab given as preoperative therapy to patients with Stage II or Stage III breast cancer	Patients will be evaluated for adverse events (all grades) at each study visit for the duration of their participation in the study. All AEs should be graded using the NCI--CTCAE, Version 3.0. Patients discontinued from the treatment phase of the study for any reason will be evaluated within 30 days after the decision to discontinue treatment.	4 years
•To estimate change from baseline expression of HIF1α as a measure of tumor angiogenesis, after a single dose of bevacizumab as compared to placebo		4 years

Secondary Outcome Measures

Outcome Measure	Time Frame
•To estimate the rate of CHF in patients receiving TAC with or without bevacizumab	4 years
•To estimate the rates of left ventricular ejection fraction (LVEF) changes as measured by either a decrease of > 15% from baseline, or > 10% to a value below the lower limit of normal (for the institution), in patients receiving TAC or TAC + bevacizumab	4 years
•To investigate the clinical efficacy of TAC and TAC plus bevacizumab by estimating the clinical objective response rate (CR + PR), pathologic complete response rate (pCR), and rate of breast-conserving surgery (BCS)	4 years
•To estimate the rate of post-surgical wound healing complications in patients who receive surgery after TAC or TAC plus bevacizumab	4 years

Collaborators and Investigators

• Sponsor: Translational Oncology Research International
• Collaborators: Genentech, Inc.
• Investigators: Study Chair: Fairooz Kabbinavar, MD, Chief Medical Officer

Study record dates

Study Major Dates

• Study Start: May 1, 2005
• Primary Completion (Actual): June 1, 2012

Study Registration Dates

• First Submitted: September 12, 2005
• First Submitted That Met QC Criteria: September 12, 2005
• First Posted (Estimate): September 20, 2005

Study Record Updates

• Last Update Posted (Estimate): October 12, 2015
• Last Update Submitted That Met QC Criteria: October 9, 2015
• Last Verified: February 1, 2011

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antibiotics, Antineoplastic; Docetaxel; Cyclophosphamide; Bevacizumab; Doxorubicin
• Other Study ID Numbers: TORI B-02; 10-001419 (Other Identifier: JCCC IRB)